Status: Recruiting
Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.
Participants needed: 20
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Williams Cancer FoundationUpdated: Apr 6, 2025Locations: 1
Eligibility criteria
Male or female, aged >18 years old at the time of signed informed consent [+14]
Has a known additional malignancy that is progressing or has required active tre... [+15]